-transparent.png){kind=logo}
Fluperlapine (NB-106-689) was tested on 26 schizophrenic patients in an open and crossover study. In addition to its good antipsychotic effect, it also alleviated the apathic and depressive syndromes. Six patients who had shown only slight or no improvement after 4 weeks of haloperidol therapy responded positively to fluperlapine. The alleviation of the anergic syndrome was especially impressive. The therapeutic response of the depressive-apathic syndromes could represent an important extension of pharmacotherapy for schizophrenia. The virtual lack of extrapyramidal motor side effects with fluperlapine supports an intensification of the search for other nonclassic dibenzo-epine neuroleptics.
K Mann, and
M Bartels, and
H J Gärtner, and
H W Schied, and
W Wagner, and
H Heimann
February 1987,
Pharmacopsychiatry,
K Mann, and
M Bartels, and
H J Gärtner, and
H W Schied, and
W Wagner, and
H Heimann
May 1973,
Activitas nervosa superior,
K Mann, and
M Bartels, and
H J Gärtner, and
H W Schied, and
W Wagner, and
H Heimann
September 1963,
El Dia medico,
K Mann, and
M Bartels, and
H J Gärtner, and
H W Schied, and
W Wagner, and
H Heimann
October 1985,
Archives internationales de pharmacodynamie et de therapie,
K Mann, and
M Bartels, and
H J Gärtner, and
H W Schied, and
W Wagner, and
H Heimann
August 1963,
Prensa medica argentina,
K Mann, and
M Bartels, and
H J Gärtner, and
H W Schied, and
W Wagner, and
H Heimann
October 1980,
Acta psychiatrica Scandinavica,
K Mann, and
M Bartels, and
H J Gärtner, and
H W Schied, and
W Wagner, and
H Heimann
January 2004,
European journal of pharmacology,
K Mann, and
M Bartels, and
H J Gärtner, and
H W Schied, and
W Wagner, and
H Heimann
January 1984,
L'Encephale,
K Mann, and
M Bartels, and
H J Gärtner, and
H W Schied, and
W Wagner, and
H Heimann
October 1987,
Journal of clinical psychopharmacology,
K Mann, and
M Bartels, and
H J Gärtner, and
H W Schied, and
W Wagner, and
H Heimann
December 2011,
Journal of clinical psychopharmacology,
